Institution
University of Texas Health Science Center at Houston
Education•Houston, Texas, United States•
About: University of Texas Health Science Center at Houston is a education organization based out in Houston, Texas, United States. It is known for research contribution in the topics: Population & Cancer. The organization has 27309 authors who have published 42520 publications receiving 2151596 citations. The organization is also known as: UTHealth & The UT Health Science Center at Houston.
Topics: Population, Cancer, Poison control, Medicine, Health care
Papers published on a yearly basis
Papers
More filters
TL;DR: The most common and significant complications are respiratory and renal failure and failure to recognize and treat ACS is inevitably fatal.
520 citations
University of Cologne1, University of Genoa2, Post Graduate Institute of Medical Education and Research3, University of Sydney4, Westmead Hospital5, Federal University of São Paulo6, University of California, San Diego7, Medical University of Graz8, Innsbruck Medical University9, University of Lagos10, McGill University Health Centre11, Fudan University12, Radboud University Nijmegen13, University of Rennes14, Duke University15, University of Texas at Austin16, University of Texas Health Science Center at San Antonio17, Federal University of Paraná18, University of Texas Health Science Center at Houston19, Cardiff University20, Center for Infectious Disease Research and Policy21
TL;DR: It is proposed to be defined as possible, probable, or proven on the basis of sample validity and thus diagnostic certainty, and recommended first-line therapy is either voriconazole or isavuconazole, while azole resistance is a concern.
Abstract: Severe acute respiratory syndrome coronavirus 2 causes direct damage to the airway epithelium, enabling aspergillus invasion. Reports of COVID-19-associated pulmonary aspergillosis have raised concerns about it worsening the disease course of COVID-19 and increasing mortality. Additionally, the first cases of COVID-19-associated pulmonary aspergillosis caused by azole-resistant aspergillus have been reported. This article constitutes a consensus statement on defining and managing COVID-19-associated pulmonary aspergillosis, prepared by experts and endorsed by medical mycology societies. COVID-19-associated pulmonary aspergillosis is proposed to be defined as possible, probable, or proven on the basis of sample validity and thus diagnostic certainty. Recommended first-line therapy is either voriconazole or isavuconazole. If azole resistance is a concern, then liposomal amphotericin B is the drug of choice. Our aim is to provide definitions for clinical research and up-to-date recommendations for clinical management of the diagnosis and treatment of COVID-19-associated pulmonary aspergillosis.
519 citations
University of Washington1, Johns Hopkins University2, University of Texas Health Science Center at Houston3, University of British Columbia4, Washington University in St. Louis5, National Institutes of Health6, University of Michigan7, Vanderbilt University8, University of Southern California9, University of Hawaii at Manoa10, Mayo Clinic11, Northwestern University12, University of Pittsburgh13, University of Iowa14, Statens Serum Institut15, Harvard University16, Fred Hutchinson Cancer Research Center17, Memorial Sloan Kettering Cancer Center18, Broad Institute19
TL;DR: Clonal mosaicism for large chromosomal anomalies (duplications, deletions and uniparental disomy) is detected using SNP microarray data from over 50,000 subjects recruited for genome-wide association studies to identify common deleted regions with genes previously associated with hematological cancers.
Abstract: We detected clonal mosaicism for large chromosomal anomalies (duplications, deletions and uniparental disomy) using SNP microarray data from over 50,000 subjects recruited for genome-wide association studies. This detection method requires a relatively high frequency of cells with the same abnormal karyotype (>5-10%; presumably of clonal origin) in the presence of normal cells. The frequency of detectable clonal mosaicism in peripheral blood is low (<0.5%) from birth until 50 years of age, after which it rapidly rises to 2-3% in the elderly. Many of the mosaic anomalies are characteristic of those found in hematological cancers and identify common deleted regions with genes previously associated with these cancers. Although only 3% of subjects with detectable clonal mosaicism had any record of hematological cancer before DNA sampling, those without a previous diagnosis have an estimated tenfold higher risk of a subsequent hematological cancer (95% confidence interval = 6-18).
519 citations
TL;DR: The authors designed a treatment to systematically increase exposure to positive activities, and thereby improve affect and corresponding cognitions and provides the treatment in manual form to be utilized by patients in therapy.
Abstract: The brief behavioral activation treatment for depression is a simple, cost-effective method for treating depression Based on basic behavioral theory and recent evidence that the behavioral component may be the active mechanism of change in cognitive-behavioral treatments of clinical depression, the authors designed a treatment to systematically increase exposure to positive activities, and thereby improve affect and corresponding cognitions This article describes the rationale for the treatment and provides the treatment in manual form to be utilized by patients in therapy
517 citations
TL;DR: It is shown that HER2 enhances the expression of CXCR4, which is required for HER2-mediated invasion in vitro and lung metastasis in vivo, and this work establishes a functional link between HER2 and CX CR4 signaling pathways.
515 citations
Authors
Showing all 27450 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Paul M. Ridker | 233 | 1242 | 245097 |
| Eugene Braunwald | 230 | 1711 | 264576 |
| Eric N. Olson | 206 | 814 | 144586 |
| Hagop M. Kantarjian | 204 | 3708 | 210208 |
| André G. Uitterlinden | 199 | 1229 | 156747 |
| Gordon B. Mills | 187 | 1273 | 186451 |
| Eric Boerwinkle | 183 | 1321 | 170971 |
| Bruce M. Psaty | 181 | 1205 | 138244 |
| Aaron R. Folsom | 181 | 1118 | 134044 |
| Daniel R. Weinberger | 177 | 879 | 128450 |
| Bharat B. Aggarwal | 175 | 706 | 116213 |
| Richard A. Gibbs | 172 | 889 | 249708 |
| Russel J. Reiter | 169 | 1646 | 121010 |
| James F. Sallis | 169 | 825 | 144836 |
| Steven N. Blair | 165 | 879 | 132929 |